Abstract Body

Background

Mycoplasma genitalium (Mgen) is increasingly recognized as an important pathogen for sexually transmitted infections (STI). As a means to develop internal testing and treatment guidelines, we sought to characterize the patient demographics and treatment outcomes of Mgen cases at our large, community-based health center with multiple sites across Chicago, IL. 

Methods

We analyzed the results of all Mgen nucleic-acid amplification tests (NAAT) performed at Howard Brown Health from January 1, 2024, to June 15, 2025. We collected information related to anatomic testing site, age, gender identity, sexual orientation, and repeatedly positive tests. Among those who had more than one positive test result, we also collected information on treatment and outcomes.  

Results

During the time frame, 2,756 Mgen NAAT tests were performed among 2,017 symptomatic or exposed individuals; of those, 381(13.8%) tests resulted as positive. Cisgender men comprised the majority of those tested (1793 tests, 65.1%) as well as with positive results (270, 70.9%). Heterosexual cisgender men represented the highest proportion of positive tests (32.3%) followed by cisgender men who have sex with men (MSM) (29.4%) and cisgender women who have sex with men (19.2%). Transgender and non-binary patients were less frequently tested and had lower overall positivity rates. Thirty-nine individuals had more than one positive test, with 10 having ≥3 positive tests. Most cases were initially treated with doxycycline followed by moxifloxacin as the first regimen. All recurrent cases were successfully treated (defined as resolution symptoms and/or repeat negative testing), either by repeating the initial treatment or using salvage regimens. Salvage regimens included minocycline monotherapy, minocycline and metronidazole combination therapy, and doxycycline or minocycline followed by tinidazole.   

Conclusions

Mgen represents an emerging STI pathogen across multiple patient populations, including heterosexual populations. On-going prospective surveillance of Mgen cases can inform guidelines for timely detection and appropriate treatment, including for refractory or recurrent cases.